| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/19/2012 | US20120094926 Compounds for enzyme inhibition |
| 04/19/2012 | US20120094925 Insulin-like growth factor binding protein 7 for treatment of cancer |
| 04/19/2012 | US20120094924 Nucleic acid delivery compounds |
| 04/19/2012 | US20120094923 Methods and materials for assessing prostate cancer recurrence and reducing mesotrypsin activity |
| 04/19/2012 | US20120094922 Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity |
| 04/19/2012 | US20120094917 Iap inhibitors |
| 04/19/2012 | US20120094904 Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof |
| 04/19/2012 | US20120094900 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof |
| 04/19/2012 | US20120094893 Method of using diketopiperazines and composition containing them |
| 04/19/2012 | US20120094892 Prodrugs |
| 04/19/2012 | US20120093941 Neutrophil-depleted platelet rich plasma formulations for cardiac treatments |
| 04/19/2012 | US20120093937 Encapsulated liver cell composition |
| 04/19/2012 | US20120093936 Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
| 04/19/2012 | US20120093932 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof |
| 04/19/2012 | US20120093921 Immunogenic compositions having low sodium chloride concentration |
| 04/19/2012 | US20120093920 Method of treatment for bladder dysfunction |
| 04/19/2012 | US20120093919 E2f as a target of hormone refractory prostate cancer |
| 04/19/2012 | US20120093918 Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof |
| 04/19/2012 | US20120093917 Metnase and intnase inhibitors and their use in treating cancer |
| 04/19/2012 | US20120093915 Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids |
| 04/19/2012 | US20120093914 Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration |
| 04/19/2012 | US20120093891 Macrocyclic lactone compounds and methods for their use |
| 04/19/2012 | US20120093888 micro-emulsions for the treatment of rheumatic disorders |
| 04/19/2012 | US20120093875 Aminocyclitol compounds, process for obtaining them and uses |
| 04/19/2012 | US20120093872 Method For Polypeptide Transfer Into Cells |
| 04/19/2012 | US20120093853 Simian Adenovirus Vectors and Methods of Use |
| 04/19/2012 | US20120093845 Neil3 peptides and vaccines including the same |
| 04/19/2012 | US20120093843 Tem8 peptides and vaccines comprising the same |
| 04/19/2012 | US20120093842 Chimeric receptor genes and cells transformed therewith |
| 04/19/2012 | US20120093841 Her2 DNA Vaccine as Adjunct Treatment for Cancers in Companion Animals |
| 04/19/2012 | US20120093838 Gene detection assay for improving the likelihood of an effective response to a her2 antibody cancer therapy |
| 04/19/2012 | US20120093837 Compositions and methods for detecting egfr in cancer |
| 04/19/2012 | US20120093836 Pharmaceutical compositions for treating metastasis |
| 04/19/2012 | US20120093833 Human Oncostatin M Antibodies and Methods of Use |
| 04/19/2012 | US20120093831 Methods and materials for modulating resistance to apoptosis |
| 04/19/2012 | US20120093830 Single domain antibodies that bind il-13 |
| 04/19/2012 | US20120093826 Fully human antibodies specific to cadm1 |
| 04/19/2012 | US20120093821 Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| 04/19/2012 | US20120093820 Prostatitis-Associated Antigens and Methods of Use Thereof |
| 04/19/2012 | US20120093819 Antibodies that specifically block the biological activity of a tumor antigen |
| 04/19/2012 | US20120093813 Anti notch-1 antibodies |
| 04/19/2012 | US20120093811 Anti-vegf-d antibodies |
| 04/19/2012 | US20120093809 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms |
| 04/19/2012 | US20120093807 Ror alpha promoting the induction of bmall |
| 04/19/2012 | US20120093806 Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine |
| 04/19/2012 | US20120093805 Anti-cd27 humanized monoclonal antibody |
| 04/19/2012 | US20120093796 Novel use of ec-sod and method for preparing thereof |
| 04/19/2012 | US20120093792 Immunotherapy for pancreatic cancer |
| 04/19/2012 | US20120093784 Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation |
| 04/19/2012 | US20120093782 Enhanced Hematopoietic Stem Cell Engraftment |
| 04/19/2012 | US20120093780 Process for producing poxviruses and poxvirus compositions |
| 04/19/2012 | US20120093773 Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same |
| 04/19/2012 | US20120093770 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| 04/19/2012 | US20120093762 Nucleic acid delivery compounds |
| 04/19/2012 | US20120093761 Vaccine compositions and methods of use thereof |
| 04/19/2012 | US20120093729 Novel phosphorus-containing prodrugs |
| 04/19/2012 | US20120093728 Mitochondrial inhibitors to treat human disease |
| 04/19/2012 | US20120093725 Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies |
| 04/19/2012 | US20120093724 Methods and compositions for the detection of cancer |
| 04/19/2012 | US20120093719 Antibodies against prostate specific membrane antigen |
| 04/19/2012 | US20120093718 Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| 04/19/2012 | US20120093716 Use of antisecretory factors (af) for optimizing cellular uptake |
| 04/19/2012 | DE102010048374A1 Pyrrolidinone als MetAP-2 Inhibitoren Pyrrolidinone as MetAP-2 inhibitors |
| 04/19/2012 | DE102010014412A1 Use of dinuclear iron complexes having sulfur-containing ligands as carbon monoxide-releasing pharmacological agents e.g. for treating hypertension, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis or sepsis |
| 04/19/2012 | CA2851694A1 Treatment of cancer/inhibition of metastasis |
| 04/19/2012 | CA2814696A1 Pharmaceutical formulation for histone deacetylase inhibitors |
| 04/19/2012 | CA2814670A1 Egfr-based peptides |
| 04/19/2012 | CA2814369A1 Pyrrolidinones as metap-2 inhibitors |
| 04/19/2012 | CA2814097A1 Composition for treating cancer by the controlled release of an active substance |
| 04/19/2012 | CA2813743A1 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
| 04/19/2012 | CA2813711A1 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| 04/19/2012 | CA2812948A1 Nd2 peptides and methods of treating neurological disease |
| 04/19/2012 | CA2810900A1 Methods for inhibiting cell proliferation in egfr-driven cancers |
| 04/19/2012 | CA2799442A1 Bacterial ribonucleic acid cell wall compositions and methods of making and using them |
| 04/18/2012 | EP2441836A1 Compound inhibiting TP53INP1 activity for the treatment of prostate cancer, and its use in screening and diagnostic methods |
| 04/18/2012 | EP2441777A2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 04/18/2012 | EP2441768A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| 04/18/2012 | EP2441757A1 Aurora kinase inhibitors from an encoded small molecule library |
| 04/18/2012 | EP2441753A1 Tetracyclic compound |
| 04/18/2012 | EP2441732A1 Carbon-bearing nsp3 nanoparticle and a method for the production thereof |
| 04/18/2012 | EP2441464A1 Specific therapy and medicament using integrin ligands for treating cancer |
| 04/18/2012 | EP2441454A1 The use of isothiocyanates compounds in treating prostatic diseases and skin cancer |
| 04/18/2012 | EP2441452A1 Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
| 04/18/2012 | EP2440571A1 Production and use of antitumoral, antibiotic and insecticidal cyclodepsipeptides |
| 04/18/2012 | EP2440559A2 Egfr inhibitors and methods of treating disorders |
| 04/18/2012 | EP2440549A1 2, 3-dihydro-1h-indene compounds and their use to treat cancer |
| 04/18/2012 | EP2440548A1 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
| 04/18/2012 | EP2440544A1 Hedgehog pathway antagonists and therapeutic applications thereof |
| 04/18/2012 | EP2440535A1 Antifungal 1,2,4-triazolyl derivatives having a 5- sulfur substituent |
| 04/18/2012 | EP2440527A1 Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase |
| 04/18/2012 | EP2440253A2 Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells |
| 04/18/2012 | EP2440250A1 Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
| 04/18/2012 | EP2440247A1 Targeted nano-photomedicines for photodynamic therapy of cancer |
| 04/18/2012 | EP2440238A1 Methods of treatment |
| 04/18/2012 | EP2440226A1 Vaccine therapy for choroidal neovascularization |
| 04/18/2012 | EP2440203A1 Small molecule inhibitors of polynucleotide kinase/phosphatase. poly(adp-ribose) polymerase and uses thereof |
| 04/18/2012 | EP2440198A2 Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms |
| 04/18/2012 | EP2440197A1 Therapeutical use of ternary complexes of valproic acid |
| 04/18/2012 | EP2440195A1 Use of alkylglycerols for preparing drugs |
| 04/18/2012 | EP2440058A1 Fused heterocyclic compounds and their uses |